- Conditions
- Heart Failure With Reduced Ejection Fraction
- Interventions
- Email Nudge
- Other
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Los Angeles, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 97–120
of 9,204
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Musculoskeletal Injury, Hypogonadism, Hormonal Contraception
- Interventions
- Goserelin 3.6 MG, Multi-Stressor Training, Testosterone gel (AndroGel 5g), Testosterone gel (AndroGel 1.25g)
- Drug · Other
- Lead sponsor
- Bradley Nindl
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Advanced Solid Tumor
- Interventions
- DB-1310, Trastuzumab, Osimertinib, capecitabine
- Drug
- Lead sponsor
- DualityBio Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 15
- States / cities
- Sacramento, California • Santa Monica, California • Coral Gables, Florida + 12 more
- Conditions
- Cataracts
- Interventions
- Intervention
- Device
- Lead sponsor
- Johnson & Johnson Surgical Vision, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 4
- States / cities
- Bakersfield, California • Venice, Florida • Mt. Pleasant, South Carolina + 1 more
- Conditions
- Food Allergies
- Interventions
- Food Drops: Food Allergens (peptides)
- Other
- Lead sponsor
- University of Missouri-Columbia
- Other
- Eligibility
- 4 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 1
- States / cities
- Columbia, Missouri
- Conditions
- Urinary Incontinence, Urge
- Interventions
- InterStim® device, Botox® injection
- Device · Drug
- Lead sponsor
- NICHD Pelvic Floor Disorders Network
- Network
- Eligibility
- 21 Years and older · Female only
- Enrollment
- 386 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • La Jolla, California • Albuquerque, New Mexico + 6 more
- Conditions
- Peripheral Artery Disease
- Interventions
- Ankle Splint
- Device
- Lead sponsor
- Florida State University
- Other
- Eligibility
- 40 Years to 100 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Alcohol Dependence, Alcohol Withdrawal Syndrome, Trauma, Heavy Drinking, Alcohol Use Disorder
- Interventions
- Valproate, Lorazepam
- Drug
- Lead sponsor
- CAMC Health System
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 2
- States / cities
- Charleston, West Virginia
- Conditions
- Liver Transplant
- Interventions
- Group 1 Donor Specific Regulation (DSR) +, Mycophenolic acid (MPA) monotherapy, data and sample collection
- Drug · Other
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Actinic Keratoses
- Interventions
- BF-200 ALA and red light LED lamp, Vehicle and red light LED lamp
- Combination Product
- Lead sponsor
- Biofrontera Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 172 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Greenwood Village, Colorado • Delray Beach, Florida + 10 more
- Conditions
- Pancreatic Cancer
- Interventions
- Volociximab, Gemcitabine
- Drug
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 2
- States / cities
- Pittsburgh, Pennsylvania • Nashville, Tennessee
- Conditions
- Diabetic Retinopathy
- Interventions
- Ketorolac 0.45% ophthalmic solution, Placebo - Preservative-free artificial tears, Aqueous PGE2 and inflammatory cytokines measurements
- Drug · Other
- Lead sponsor
- Stephen J. Kim, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- HIV-1 Infection
- Interventions
- E/C/F/TAF
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 3
- States / cities
- Ft. Pierce, Florida • Orlando, Florida • West Palm Beach, Florida
- Conditions
- Laparoscopic Colorectal Resection
- Interventions
- TAP block, Epidural, Paravertebral block, Acetaminophen 1g IV, Dexamethasone 4mg, Midazolam up to 2mg, Propofol 1-2.5 mg/kg, Sevoflurane to keep a bispectral index of between 40-60, Local infiltration with 10 mL of plain ropivacaine 0.25%, Lidocaine, Epinephrine, Hydromorphone
- Procedure · Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Foot Ulcer, Diabetic, Infection
- Interventions
- Gentamicin collagen sponge, Placebo
- Drug · Other
- Lead sponsor
- Innocoll
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 612 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 86
- States / cities
- Anniston, Alabama • Mobile, Alabama • Mesa, Arizona + 67 more
- Conditions
- Dietary Change, Obesity & Overweight, Food Acceptance
- Interventions
- Pistachios, Dual-energy X-ray absorptiometry (DEXA) scans
- Dietary Supplement · Procedure
- Lead sponsor
- Ian J. Neeland, MD
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 108 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Clevland, Ohio
- Conditions
- Interpersonal Relations
- Interventions
- SSGRIN-Parent Guide
- Behavioral
- Lead sponsor
- Duke University
- Other
- Eligibility
- 8 Years to 12 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2012
- U.S. locations
- 2
- States / cities
- Cary, North Carolina • Durham, North Carolina
- Conditions
- Onychomycosis of Toenail
- Interventions
- Efinaconazole 10% Topical Application Solution [JUBLIA], Application of Nail Polish
- Drug · Other
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 19 Years to 70 Years · Female only
- Enrollment
- 13 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Binge-Eating Disorder, Bulimia Nervosa
- Interventions
- CBT, ICT
- Behavioral
- Lead sponsor
- Drexel University
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Meniscus Tear, Tibial
- Interventions
- Non-Operative Pain Management, Operative treatment arm will undergo transtibial medial meniscus root repair within 3 weeks of enrollment
- Other · Procedure
- Lead sponsor
- Rush University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2030
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Childhood Myelodysplastic Syndromes, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Disseminated Neuroblastoma, Malignant Neoplasm, Ovarian Choriocarcinoma, Ovarian Embryonal Carcinoma, Ovarian Immature Teratoma, Ovarian Mature Teratoma, Ovarian Mixed Germ Cell Tumor, Ovarian Monodermal and Highly Specialized Teratoma, Ovarian Polyembryoma, Ovarian Yolk Sac Tumor, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Mantle Cell Lymphoma, Recurrent Neuroblastoma, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Refractory Chronic Lymphocytic Leukemia, Refractory Multiple Myeloma, Relapsing Chronic Myelogenous Leukemia, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage II Ovarian Epithelial Cancer, Stage III Malignant Testicular Germ Cell Tumor, Stage III Multiple Myeloma, Stage III Ovarian Epithelial Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IV Ovarian Epithelial Cancer, Testicular Choriocarcinoma, Testicular Choriocarcinoma and Embryonal Carcinoma, Testicular Choriocarcinoma and Seminoma, Testicular Choriocarcinoma and Teratoma, Testicular Choriocarcinoma and Yolk Sac Tumor, Testicular Embryonal Carcinoma, Testicular Embryonal Carcinoma and Seminoma, Testicular Embryonal Carcinoma and Teratoma, Testicular Embryonal Carcinoma and Teratoma With Seminoma, Testicular Embryonal Carcinoma and Yolk Sac Tumor, Testicular Embryonal Carcinoma and Yolk Sac Tumor With Seminoma, Testicular Teratoma, Testicular Yolk Sac Tumor, Testicular Yolk Sac Tumor and Teratoma, Testicular Yolk Sac Tumor and Teratoma With Seminoma
- Interventions
- ipilimumab, therapeutic allogeneic lymphocytes
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 5
- States / cities
- La Jolla, California • Atlanta, Georgia • Boston, Massachusetts
- Conditions
- Neurofibromatosis Type 1, Plexiform Neurofibromas
- Interventions
- Acceptance and Commitment Therapy (ACT)
- Behavioral
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 16 Years to 59 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Diabetic Macular Edema
- Interventions
- Laser Photocoagulation, Intravitreal Aflibercept Injection
- Procedure · Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 221 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 42
- States / cities
- Artesia, California • Beverly Hills, California • Mountain View, California + 38 more
- Conditions
- EGFR Gene Mutation, Glioblastoma, MGMT-Unmethylated Glioblastoma, Recurrent Glioblastoma
- Interventions
- E-SYNC T Cells, Cyclophosphamide (non-investigational), Fludarabine (non-investigational), Leukapheresis, Surgical resection
- Biological · Drug · Procedure
- Lead sponsor
- Hideho Okada, MD, PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- San Francisco, California